Abstract 133 Table 1

First author and year and locationStudy typeAge range of patientsNumber of patients in controlNumber of patients in treatmentDosage of riboflavinSeverity of migraineDecrease in frequency or duration
Athaillah, 2012
Indonesia 		Randomised
Double Blind 		12–19 years 48 50 400 mg daily Reduction in severity in 94% of Riboflavin Group vs 14.6% of controls after 3 months* 0% in Riboflavin vs 38% of controls had HA more than 2 hours*
Brujin, 2010
Netherlands 		Randomised
Double Blind-Cross Over 		6–13 years 22 20 50 mg daily Frequency 1.55/month in Riboflavin vs 1.66/month of controls (p=0.44) Decrease in tension phenotype in favour of Riboflavin group*
Condo, 2010
Italy 		Retrospective 8–18 years Patients compared to baseline 40 200 or 400 mg daily Severity decreased from 2 to 1.4 after 3 months* Frequency decreased from 23.4 to 8.9 after 3 months*
MacLennan, 2008
Australia 		Randomised
Double Blind 		5–15 years 21 children 27 children 200 mg daily No difference in severity in the 2 groups 50% decrease in 44% of riboflavin vs 67% of placebo (p=0.125)

  • *P value